Artículos por temáticas

En este apartado encontrará una actualización mensual de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por la International Parkinson & Movement Disorder Society.

FILTRAR POR:

Tema

Trastornos del movimiento Enfermedad de Parkinson Distonía Corea y enfermedad de Huntington Ataxia Temblor y temblor esencial Mioclonía y espasmos Tics y síndrome de Tourette Síndrome de piernas inquietas Síndrome de la persona rígida Alteraciones de la marcha Espasticidad COVID-19 y Enfermedades Neurológicas Biomarcadores Demencia Diagnosis Epidemiologia Fisiopatología Síntomas cognitivos y conductales Tratamiento farmacologico Tratamiento no farmacológico

Año

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Tratamiento farmacologico

373 ARTíCULOS , VIENDO DEL 361 AL 373

PUBMED

Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease

Cho JE, Kim JR.

Recent Pat CNS Drug Discov. 2011 Sep 1;6(3):222-33. doi: 10.2174/157488911796958002.

PUBMED

[Role of the blood-brain barrier in Alzheimer's disease]

Gosselet F, Candela P, Cecchelli R, Fenart L.

Med Sci (Paris). 2011 Nov;27(11):987-92. doi: 10.1051/medsci/20112711015. Epub 2011 Nov 30.

PUBMED

Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease

Weiner MW, Sadowsky C, Saxton J, Hofbauer RK, Graham SM, Yu SY, Li S, Hsu HA, Suhy J, Fridman M, Perhach JL.

Alzheimers Dement. 2011 Jul;7(4):425-35. doi: 10.1016/j.jalz.2010.09.003. Epub 2011 Jun 8.

PUBMED

Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type

Dhillon S.

Drugs Aging. 2011 Nov 1;28(11):927-30. doi: 10.2165/11207090-000000000-00000.

PUBMED

Alzheimer's disease: emerging trends in small molecule therapies

Mohamed T, Rao PP.

Curr Med Chem. 2011;18(28):4299-320. doi: 10.2174/092986711797200435.

PUBMED

Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine

Anekonda TS, Quinn JF.

Biochim Biophys Acta. 2011 Dec;1812(12):1584-90. doi: 10.1016/j.bbadis.2011.08.013. Epub 2011 Sep 8.

PUBMED

Aβ-degrading enzymes: potential for treatment of Alzheimer disease

Miners JS, Barua N, Kehoe PG, Gill S, Love S.

J Neuropathol Exp Neurol. 2011 Nov;70(11):944-59. doi: 10.1097/NEN.0b013e3182345e46.

PUBMED

Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy

Delrieu J, Piau A, Caillaud C, Voisin T, Vellas B.

CNS Drugs. 2011 Mar;25(3):213-26. doi: 10.2165/11539810-000000000-00000.

PUBMED

Ginseng

Barton D.

Oncology (Williston Park). 2011 Apr;25(4 Suppl Nurse Ed):42-5.

PUBMED

[Rivastigmine]

Monji A.

Nihon Rinsho. 2011 Dec;69 Suppl 10 Pt 2:36-40.

PUBMED

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

Karran E, Mercken M, De Strooper B.

Nat Rev Drug Discov. 2011 Aug 19;10(9):698-712. doi: 10.1038/nrd3505.

PUBMED

Amyloid-dependent and amyloid-independent stages of Alzheimer disease

Hyman BT.

Arch Neurol. 2011 Aug;68(8):1062-4. doi: 10.1001/archneurol.2011.70. Epub 2011 Apr 11.

PUBMED

Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association

Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, L

Stroke. 2011 Sep;42(9):2672-713. doi: 10.1161/STR.0b013e3182299496. Epub 2011 Jul 21.

Artículos por temáticas

Tratamiento farmacologico

Comentarios